Holding(s) in Company

Allergy Therapeutics PLC 11 May 2005 Schedule 10 NOTIFICATION OF MAJOR INTERSTS IN SHARES 1. Name of Company Allergy Therapeutics plc 2. Name of shareholder having a major interest Fidelity International Limited 3. Please state whether notification indicates that it is in respect of holding of the shareholder names in 2 above or in respect of a non-beneficial interest or in the case of children under the age of 18 Non-beneficial interest 4. Name of the registered holder(s) and, if more than one holder, the number of share held by each of them Nominee/registered name Share held Management Company JP Morgan, Bournemouth 1,572,100 Fidelity Inv Services Ltd Bank of New York, Brussels 359,662 Fidelity Pension Mgmnt(FPM) Bankers Trust London 135,700 FPM CITIBANK London 128,400 FPM Clydesdale Bank plc 71,900 FPM JP Morgan, Bournemouth 288,500 FPM Mellon Bank 325,400 FPM Midland Securities Services 74,300 FPM Northern Trust London 618,500 FPM State STR BK and TR Co London 227,084 FPM Brown Bros Harrimn Ltd LUX 650,000 FPM Bank of New York, Brussels 81,900 FIL 5. Number of shares/amount of stock acquired 650,000 6. Percentage of issued class 1.03% 7. Number of shares/amount of stock disposed - 8. Percentage of issued class - 9. Class of security Ordinary shares 10. Date of transaction Not notified 11. Date company informed 10th May 2005 12. Total holding following this notification 4,533,446 13. Total percentage holding of issued class following this notification 7.20% 14. Any additional items Notifiable interest also comprises of Mr.Edward C. Johnson 3d A principal Shareholder of Fidelity International Limited 15. Name of contact and telephone number for queries Ian Postlethwaite - 01903 844721 16. Name and signature of authorised company official responsible for make this notification Ian Postlethwaite Date of notification 10th May 2005 The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings